Artificial intelligence (AI) is making significant strides in the healthcare sector, particularly in pharmacy practice and medication management. A recent scoping review has shed light on the current landscape of AI applications within medicines information services, addressing critical aspects such as accuracy, content completeness and the role of healthcare professionals (HCPs) in adopting these technologies. The review emphasizes the importance of mapping how AI is utilized in this field, given the growing reliance on technology-driven solutions.
The review, adhering to the PRISMA-ScR guidelines, aims to systematically analyze various studies that explore AI’s impact on disseminating and accessing medicines information across different healthcare settings. With a focus on HCP involvement, the study seeks to answer four primary questions: the effectiveness of AI tools, the accuracy of AI-generated information, barriers to AI adoption, and the perceptions of HCPs, particularly pharmacists, regarding these technologies.
As AI continues to evolve, its potential to enhance medication management is increasingly recognized. Various reviews have highlighted the effectiveness of AI in optimizing drug safety, improving clinical decision support systems, and supporting disease management. However, the application of AI specifically for medicines information remains an underexplored area, presenting both opportunities and challenges that demand to be addressed.
Focus of the Scoping Review
The scoping review sets out to fill a significant gap in existing research by thoroughly mapping AI’s applications in medicines information. It also aims to evaluate the accuracy and completeness of AI-generated responses while identifying the challenges that may affect its adoption across diverse healthcare environments. The review highlights the crucial role pharmacists and other HCPs play in assessing and integrating AI-driven tools into their practice.
Methodology and Study Selection
The systematic literature search was conducted across multiple reputable databases, including MEDLINE, PubMed Central, and Cochrane Library, yielding 1,911 citations. After removing duplicates and screening titles and abstracts, 14 studies were included for full-text analysis. The studies varied in their methodologies, including qualitative, quantitative, and mixed methods, focusing on the role of AI in enhancing medicines information.
Key Findings on AI Tools in Medicines Information
The review assessed different AI systems, primarily those utilizing natural language processing (NLP), to generate responses related to medications. Notable tools included Microsoft Bing Copilot and Micromedex with Watson, both of which aimed to enhance medication-related queries. However, challenges such as incomplete information and readability issues were noted. The performance of AI models like ChatGPT also varied significantly, with newer versions, such as ChatGPT-4, outperforming earlier iterations in accuracy.
Despite the promising capabilities of these AI systems, the review found that many responses generated by AI could be potentially harmful or unreliable, emphasizing the necessity of HCP oversight in clinical contexts. The findings indicated that while AI tools can improve efficiency and clarity in medication counseling, they still require validation and verification by trained professionals.
Impact of Digital Health Inequalities
The review also explored the implications of digital health inequalities, which refer to disparities in access to and use of digital health technologies. Barriers such as limited internet connectivity and lack of resources were identified as significant challenges to the equitable implementation of AI in healthcare settings. The study highlighted that many pharmacists in lower-income regions faced infrastructural challenges that hindered their ability to effectively utilize AI tools.
Conclusions and Future Directions
while AI holds great promise in advancing medicines information and supporting pharmacists in their roles, its reliability, particularly in complex clinical scenarios, remains uncertain. The review calls for a comprehensive strategy to address the barriers to AI adoption, including ensuring equitable access to digital health technologies and enhancing training for HCPs. Future research should focus on improving the accuracy and effectiveness of AI in handling complex clinical inquiries, thereby ensuring that AI can serve as a reliable complement to human expertise in pharmacy practice.
As AI continues to shape the future of healthcare, the collaboration between technology and human oversight will be essential for optimizing patient outcomes and ensuring safe medication practices. Engaging in discussions about these developments can further enhance the integration of AI into pharmacy practice.
For those interested in the evolving role of AI in healthcare, this review underscores both the opportunities and challenges that lie ahead, making it an essential read for healthcare professionals and policymakers alike.
